Latest:
Treating Patients Post CAR T Therapy
David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Christine M. Lovly, MD, PhD
Latest:
Treatment Sequencing in Disease Progression in EGFRm NSCLC
Panelists discuss how, after the MARIPOSA regimen, second-line therapy selection depends on resistance mechanisms, prior toxicity, and patient factors. MARIPOSA-2 vs PALOMA-3 choices are influenced by efficacy in resistant mutations and safety profiles, per European Society for Medical Oncology 2023/2024 and American Society of Clinical Oncology 2024 data.
University of North Carolina, Lineberger Comprehensive Cancer Center
Latest:
Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center
Robert L. Ferris, MD, PhD, has been named the executive director of UNC Lineberger Comprehensive Cancer Center and UNC system chief of oncology services.
Sun-Min Lim, MD, PhD
Sun-Min Lim, MD, PhD, is an associate professor at Severance Hospital within Yonsei University Health System.
Latest:
Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC
Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.
Christine Chung, MD
Christine Chung, MD, is the program lead of Head and Neck Oncology; Research Department Chair of Head and Neck-Endocrine Oncology; chair of the Department of Head and Neck-Endocrine Oncology; and program leader of Head and Neck Oncology at Moffitt Cancer Center.
Latest:
Dr Chung on the Potential Role for Ficerafusp Alfa Plus Pembrolizumab in the HPV-Negative HNSCC Paradigm
Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.
Syed Abbas Ali, MBBS
Syed Abbas Ali, MBBS, an assistant professor of oncology at Johns Hopkins School of Medicine and Sidney Kimmel Comprehensive Cancer Center
Latest:
Dr Ali on Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in R/R Multiple Myeloma
Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.
Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center
Latest:
Treatment Approaches for TP53-Mutated AML
Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.
Tara E. Seery, MD
Latest:
Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS
Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.